Endomyocardial Biopsy Market Outlook 2026-2034: Market Share, and Growth Analysis By Product (Forceps, Accessories), By Tip (Maxi-curved, Straight, Pre-curved, Others), By End-User

The Endomyocardial Biopsy Market is valued at USD 382.8 million in 2025 and is projected to grow at a CAGR of 7.5% to reach USD 733.9 million by 2034. Endomyocardial Biopsy Market The Endomyocard... もっと見る

出版社	出版年月	電子版価格	納期	言語
OG Analysis オージーアナリシス	2025年11月11日	US$3,950 シングルユーザライセンスライセンス・価格情報注文方法はこちら	通常3-4営業日以内	英語

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。
日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。

Table of Contents

Summary

The Endomyocardial Biopsy Market is valued at USD 382.8 million in 2025 and is projected to grow at a CAGR of 7.5% to reach USD 733.9 million by 2034.

Endomyocardial Biopsy Market

The Endomyocardial Biopsy (EMB) market comprises devices, consumables, imaging support, and pathology services used to sample myocardial tissue for histology, immunohistochemistry, and molecular testing. Core end-uses include surveillance of cardiac transplant rejection, etiologic workup of suspected myocarditis, characterization of infiltrative and genetic cardiomyopathies, and investigation of unexplained heart failure or arrhythmias when results alter management. Clinical practice is shifting toward protocolized pathways: fluoroscopy remains the staple, while echocardiography and intracardiac echo broaden access in labs without hybrid suites; electro-anatomic mapping assists targeted left-sided sampling in select cases. On the device side, demand favors single-use bioptomes, lower-profile sheaths, hemostasis valves, and torqueable catheters that improve reach and reduce complications, alongside adjuncts such as pressure monitoring and ultrasound-guided venous access kits. In pathology, digital workflows, AI-assisted image analysis, viral PCR, gene expression profiling, and emerging spatial assays strengthen diagnostic yield and standardization. Growth drivers include stable transplant volumes with intensified early surveillance, heightened myocarditis recognition, precision-medicine programs linking genotype–phenotype, and expanding advanced heart-failure networks. Headwinds include procedure risk (perforation, tamponade), variable operator training, reimbursement scrutiny, and the expanding role of cardiac MRI and PET, which can triage patients away from biopsy in specific scenarios. The competitive landscape features specialized cardiovascular device manufacturers, imaging and navigation vendors, and reference pathology providers forming integrated value propositions around safety, turnaround time, and decision-impact. Over the forecast horizon, adoption will favor safer access, targeted sampling, and data-rich pathology readouts that translate tissue into actionable therapy choices.

Endomyocardial Biopsy Market Key Insights

• Transplant surveillance anchors demand. Standardized timelines for early and intermediate post-transplant monitoring sustain procedure volumes; centers differentiate via low-complication access protocols, rapid pathology turnaround, and digital scheduling to minimize readmissions and delays.
• Imaging advances elevate precision. Fluoroscopy plus echo guidance reduces perforation risk and improves sample adequacy; in complex cardiomyopathies, mapping-guided left-ventricular biopsies increase diagnostic yield when right-sided samples are non-representative.
• Device design focuses on safety and control. Smaller French sizes, improved jaw geometry, and enhanced torque transmission support consistent bites with fewer passes. Single-use bioptomes address sterility assurance and logistics, while atraumatic sheaths and closure devices streamline recovery.
• Pathology goes molecular and digital. Beyond hematoxylin–eosin and immunostains, labs deploy viral PCR, immunophenotyping, and gene expression panels to classify rejection and myocarditis subtypes. Whole-slide imaging enables remote reads, QA programs, and AI pre-screening for workload smoothing.
• Myocarditis awareness widens indications. Post-viral and immune-mediated entities drive targeted biopsies when imaging is equivocal or therapy hinges on histology. Institutions formalize multidisciplinary boards to align biopsy timing with immunosuppression decisions.
• Complication mitigation is a differentiator. Ultrasound-guided venous access, real-time pressure checks, and standardized bite counts lower adverse events. Simulation training and proctorship pathways help expand operator pools without compromising outcomes.
• Reimbursement and evidence expectations rise. Payers increasingly request documentation of diagnostic impact; programs respond with pathway metrics - adequacy rates, turnaround times, and treatment changes - demonstrating value beyond the procedural fee.
• Pediatrics and congenital cohorts need specialization. Dedicated tools and protocols for smaller anatomies, plus anesthesia and echo support, enable safe sampling in pediatric transplants and myocarditis, with central pathology review enhancing consistency.
• Alternatives reshape utilization, not relevance. Cardiac MRI and PET reduce unnecessary biopsies but also triage toward higher-yield cases; EMB remains decisive when tissue diagnosis changes immunotherapy, antiviral strategies, or graft management.
• Integration across the care continuum. Vendors bundle devices, imaging, and training; labs pair diagnostics with consultative reports and virtual tumor-board-style reviews. Data feedback loops inform access choice, sample targeting, and follow-up cadence.

Endomyocardial Biopsy Market Reginal Analysis

North America

High transplant and advanced heart-failure center density underpins steady EMB demand, with strong uptake of single-use bioptomes, echo-guided access, and digital pathology. Hospital systems emphasize complication reduction bundles and rapid, actionable reports linking histology to therapy adjustments. Academic networks lead mapping-guided LV biopsies in complex cardiomyopathies, while ambulatory and hybrid labs expand capacity. Reimbursement oversight encourages documentation of clinical impact and standardized pathways.

Europe

Guideline-driven practice supports selective but rigorous EMB use: transplant surveillance, biopsy-proven myocarditis, and infiltrative disease confirmation. Procurement favors validated single-use devices and structured reprocessing where reusables persist. University hospitals advance molecular panels and centralized digital reads to harmonize interpretations across regions. Training consortia and simulation programs address operator variability, while day-case protocols and ultrasound-guided venous access improve patient flow.

Asia-Pacific

Expanding tertiary cardiac care in China, India, Japan, South Korea, and Australia increases access to EMB, particularly in transplant hubs and metropolitan heart-failure programs. Investments prioritize fluoroscopy/echo integration, reliable disposable supply, and staff upskilling. Imaging often triages first, with biopsy reserved for management-critical decisions. Regional reference labs build capacity for molecular assays and telepathology to support secondary cities and satellite centers.

Middle East & Africa

Growth concentrates in major urban transplant and advanced cardiology centers, where turnkey catheter-lab solutions and vendor-supported training accelerate capability. Emphasis is on safety - ultrasound-guided access, standardized post-procedure monitoring, and rapid escalation pathways. Limited local pathology capacity in some markets drives partnerships with centralized labs for molecular testing and second opinions via digital platforms. Procurement values device reliability and responsive service.

South & Central America

Referral centers in Brazil, Mexico, Argentina, and Chile anchor demand, focusing on transplant follow-up and selected myocarditis workups. Programs invest in single-use device availability, echo-assisted techniques, and structured complication-avoidance checklists. Regional collaborations expand digital pathology coverage and turnaround, while public–private partnerships support training and equipment refresh. Imaging remains a strong gatekeeper, reserving EMB for cases where tissue diagnosis directs therapy.

Endomyocardial Biopsy Market Segmentation

By Product

Forceps

Accessories

By Tip

Maxi-curved

Straight

Pre-curved

Others

By End-User

Hospitals

Ambulatory Surgical Centers

Others

Key Market players

Fonterra Co-operative Group, FrieslandCampina Ingredients, Morinaga Milk Industry Co., Ltd., MILEI GmbH, Synlait Milk Ltd., Westland Milk Products, Tatua Co-operative Dairy Company, Bega Bionutrients (Tatura Milk Industries), Beston Global Food Company, Glanbia Nutritionals, Armor Protéines (Savencia), Ingredia SA, Saputo Dairy Australia, Milk Specialties Global, Hilmar Cheese Company

Endomyocardial Biopsy Market Analytics

The report employs rigorous tools, including Porter’s Five Forces, value chain mapping, and scenario-based modelling, to assess supply–demand dynamics. Cross-sector influences from parent, derived, and substitute markets are evaluated to identify risks and opportunities. Trade and pricing analytics provide an up-to-date view of international flows, including leading exporters, importers, and regional price trends. Macroeconomic indicators, policy frameworks such as carbon pricing and energy security strategies, and evolving consumer behaviour are considered in forecasting scenarios. Recent deal flows, partnerships, and technology innovations are incorporated to assess their impact on future market performance.

Endomyocardial Biopsy Market Competitive Intelligence

The competitive landscape is mapped through OG Analysis’ proprietary frameworks, profiling leading companies with details on business models, product portfolios, financial performance, and strategic initiatives. Key developments such as mergers & acquisitions, technology collaborations, investment inflows, and regional expansions are analyzed for their competitive impact. The report also identifies emerging players and innovative startups contributing to market disruption. Regional insights highlight the most promising investment destinations, regulatory landscapes, and evolving partnerships across energy and industrial corridors.

Countries Covered

North America — Endomyocardial Biopsy market data and outlook to 2034
- United States
- Canada
- Mexico
Europe — Endomyocardial Biopsy market data and outlook to 2034
- Germany
- United Kingdom
- France
- Italy
- Spain
- BeNeLux
- Russia
- Sweden
Asia-Pacific — Endomyocardial Biopsy market data and outlook to 2034
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Malaysia
- Vietnam
Middle East and Africa — Endomyocardial Biopsy market data and outlook to 2034
- Saudi Arabia
- South Africa
- Iran
- UAE
- Egypt
South and Central America — Endomyocardial Biopsy market data and outlook to 2034
- Brazil
- Argentina
- Chile
- Peru

* We can include data and analysis of additional countries on demand.

Research Methodology

This study combines primary inputs from industry experts across the Endomyocardial Biopsy value chain with secondary data from associations, government publications, trade databases, and company disclosures. Proprietary modeling techniques, including data triangulation, statistical correlation, and scenario planning, are applied to deliver reliable market sizing and forecasting.

Key Questions Addressed

What is the current and forecast market size of the Endomyocardial Biopsy industry at global, regional, and country levels?

Which types, applications, and technologies present the highest growth potential?

How are supply chains adapting to geopolitical and economic shocks?

What role do policy frameworks, trade flows, and sustainability targets play in shaping demand?

Who are the leading players, and how are their strategies evolving in the face of global uncertainty?

Which regional “hotspots” and customer segments will outpace the market, and what go-to-market and partnership models best support entry and expansion?

Where are the most investable opportunities—across technology roadmaps, sustainability-linked innovation, and M&A—and what is the best segment to invest over the next 3–5 years?

Your Key Takeaways from the Endomyocardial Biopsy Market Report

Global Endomyocardial Biopsy market size and growth projections (CAGR), 2024-2034
Impact of Russia-Ukraine, Israel-Palestine, and Hamas conflicts on Endomyocardial Biopsy trade, costs, and supply chains
Endomyocardial Biopsy market size, share, and outlook across 5 regions and 27 countries, 2023-2034
Endomyocardial Biopsy market size, CAGR, and market share of key products, applications, and end-user verticals, 2023-2034
Short- and long-term Endomyocardial Biopsy market trends, drivers, restraints, and opportunities
Porter’s Five Forces analysis, technological developments, and Endomyocardial Biopsy supply chain analysis
Endomyocardial Biopsy trade analysis, Endomyocardial Biopsy market price analysis, and Endomyocardial Biopsy supply/demand dynamics
Profiles of 5 leading companies—overview, key strategies, financials, and products
Latest Endomyocardial Biopsy market news and developments

Additional Support

With the purchase of this report, you will receive

An updated PDF report and an MS Excel data workbook containing all market tables and figures for easy analysis.
7-day post-sale analyst support for clarifications and in-scope supplementary data, ensuring the deliverable aligns precisely with your requirements.
Complimentary report update to incorporate the latest available data and the impact of recent market developments.

* The updated report will be delivered within 3 working days"

ページTOPに戻る

1. Table of Contents
1.1 List of Tables
1.2 List of Figures

2. Global Endomyocardial Biopsy Market Summary, 2025
2.1 Endomyocardial Biopsy Industry Overview
2.1.1 Global Endomyocardial Biopsy Market Revenues (In US$ billion)
2.2 Endomyocardial Biopsy Market Scope
2.3 Research Methodology

3. Endomyocardial Biopsy Market Insights, 2024-2034
3.1 Endomyocardial Biopsy Market Drivers
3.2 Endomyocardial Biopsy Market Restraints
3.3 Endomyocardial Biopsy Market Opportunities
3.4 Endomyocardial Biopsy Market Challenges
3.5 Tariff Impact on Global Endomyocardial Biopsy Supply Chain Patterns

4. Endomyocardial Biopsy Market Analytics
4.1 Endomyocardial Biopsy Market Size and Share, Key Products, 2025 Vs 2034
4.2 Endomyocardial Biopsy Market Size and Share, Dominant Applications, 2025 Vs 2034
4.3 Endomyocardial Biopsy Market Size and Share, Leading End Uses, 2025 Vs 2034
4.4 Endomyocardial Biopsy Market Size and Share, High Growth Countries, 2025 Vs 2034
4.5 Five Forces Analysis for Global Endomyocardial Biopsy Market
4.5.1 Endomyocardial Biopsy Industry Attractiveness Index, 2025
4.5.2 Endomyocardial Biopsy Supplier Intelligence
4.5.3 Endomyocardial Biopsy Buyer Intelligence
4.5.4 Endomyocardial Biopsy Competition Intelligence
4.5.5 Endomyocardial Biopsy Product Alternatives and Substitutes Intelligence
4.5.6 Endomyocardial Biopsy Market Entry Intelligence

5. Global Endomyocardial Biopsy Market Statistics – Industry Revenue, Market Share, Growth Trends and Forecast by segments, to 2034
5.1 World Endomyocardial Biopsy Market Size, Potential and Growth Outlook, 2024- 2034 ($ billion)
5.1 Global Endomyocardial Biopsy Sales Outlook and CAGR Growth By Product, 2024- 2034 ($ billion)
5.2 Global Endomyocardial Biopsy Sales Outlook and CAGR Growth By Tip, 2024- 2034 ($ billion)
5.3 Global Endomyocardial Biopsy Sales Outlook and CAGR Growth By End-User, 2024- 2034 ($ billion)
5.4 Global Endomyocardial Biopsy Market Sales Outlook and Growth by Region, 2024- 2034 ($ billion)

6. Asia Pacific Endomyocardial Biopsy Industry Statistics – Market Size, Share, Competition and Outlook
6.1 Asia Pacific Endomyocardial Biopsy Market Insights, 2025
6.2 Asia Pacific Endomyocardial Biopsy Market Revenue Forecast By Product, 2024- 2034 (USD billion)
6.3 Asia Pacific Endomyocardial Biopsy Market Revenue Forecast By Tip, 2024- 2034 (USD billion)
6.4 Asia Pacific Endomyocardial Biopsy Market Revenue Forecast By End-User, 2024- 2034 (USD billion)
6.5 Asia Pacific Endomyocardial Biopsy Market Revenue Forecast by Country, 2024- 2034 (USD billion)
6.5.1 China Endomyocardial Biopsy Market Size, Opportunities, Growth 2024- 2034
6.5.2 India Endomyocardial Biopsy Market Size, Opportunities, Growth 2024- 2034
6.5.3 Japan Endomyocardial Biopsy Market Size, Opportunities, Growth 2024- 2034
6.5.4 Australia Endomyocardial Biopsy Market Size, Opportunities, Growth 2024- 2034

7. Europe Endomyocardial Biopsy Market Data, Penetration, and Business Prospects to 2034
7.1 Europe Endomyocardial Biopsy Market Key Findings, 2025
7.2 Europe Endomyocardial Biopsy Market Size and Percentage Breakdown By Product, 2024- 2034 (USD billion)
7.3 Europe Endomyocardial Biopsy Market Size and Percentage Breakdown By Tip, 2024- 2034 (USD billion)
7.4 Europe Endomyocardial Biopsy Market Size and Percentage Breakdown By End-User, 2024- 2034 (USD billion)
7.5 Europe Endomyocardial Biopsy Market Size and Percentage Breakdown by Country, 2024- 2034 (USD billion)
7.5.1 Germany Endomyocardial Biopsy Market Size, Trends, Growth Outlook to 2034
7.5.2 United Kingdom Endomyocardial Biopsy Market Size, Trends, Growth Outlook to 2034
7.5.2 France Endomyocardial Biopsy Market Size, Trends, Growth Outlook to 2034
7.5.2 Italy Endomyocardial Biopsy Market Size, Trends, Growth Outlook to 2034
7.5.2 Spain Endomyocardial Biopsy Market Size, Trends, Growth Outlook to 2034

8. North America Endomyocardial Biopsy Market Size, Growth Trends, and Future Prospects to 2034
8.1 North America Snapshot, 2025
8.2 North America Endomyocardial Biopsy Market Analysis and Outlook By Product, 2024- 2034 ($ billion)
8.3 North America Endomyocardial Biopsy Market Analysis and Outlook By Tip, 2024- 2034 ($ billion)
8.4 North America Endomyocardial Biopsy Market Analysis and Outlook By End-User, 2024- 2034 ($ billion)
8.5 North America Endomyocardial Biopsy Market Analysis and Outlook by Country, 2024- 2034 ($ billion)
8.5.1 United States Endomyocardial Biopsy Market Size, Share, Growth Trends and Forecast, 2024- 2034
8.5.1 Canada Endomyocardial Biopsy Market Size, Share, Growth Trends and Forecast, 2024- 2034
8.5.1 Mexico Endomyocardial Biopsy Market Size, Share, Growth Trends and Forecast, 2024- 2034

9. South and Central America Endomyocardial Biopsy Market Drivers, Challenges, and Future Prospects
9.1 Latin America Endomyocardial Biopsy Market Data, 2025
9.2 Latin America Endomyocardial Biopsy Market Future By Product, 2024- 2034 ($ billion)
9.3 Latin America Endomyocardial Biopsy Market Future By Tip, 2024- 2034 ($ billion)
9.4 Latin America Endomyocardial Biopsy Market Future By End-User, 2024- 2034 ($ billion)
9.5 Latin America Endomyocardial Biopsy Market Future by Country, 2024- 2034 ($ billion)
9.5.1 Brazil Endomyocardial Biopsy Market Size, Share and Opportunities to 2034
9.5.2 Argentina Endomyocardial Biopsy Market Size, Share and Opportunities to 2034

10. Middle East Africa Endomyocardial Biopsy Market Outlook and Growth Prospects
10.1 Middle East Africa Overview, 2025
10.2 Middle East Africa Endomyocardial Biopsy Market Statistics By Product, 2024- 2034 (USD billion)
10.3 Middle East Africa Endomyocardial Biopsy Market Statistics By Tip, 2024- 2034 (USD billion)
10.4 Middle East Africa Endomyocardial Biopsy Market Statistics By End-User, 2024- 2034 (USD billion)
10.5 Middle East Africa Endomyocardial Biopsy Market Statistics by Country, 2024- 2034 (USD billion)
10.5.1 Middle East Endomyocardial Biopsy Market Value, Trends, Growth Forecasts to 2034
10.5.2 Africa Endomyocardial Biopsy Market Value, Trends, Growth Forecasts to 2034

11. Endomyocardial Biopsy Market Structure and Competitive Landscape
11.1 Key Companies in Endomyocardial Biopsy Industry
11.2 Endomyocardial Biopsy Business Overview
11.3 Endomyocardial Biopsy Product Portfolio Analysis
11.4 Financial Analysis
11.5 SWOT Analysis

12 Appendix
12.1 Global Endomyocardial Biopsy Market Volume (Tons)
12.1 Global Endomyocardial Biopsy Trade and Price Analysis
12.2 Endomyocardial Biopsy Parent Market and Other Relevant Analysis
12.3 Publisher Expertise
12.2 Endomyocardial Biopsy Industry Report Sources and Methodology

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医療）の最新刊レポート

OG Analysis社のヘルスケア・医薬品分野での最新刊レポート

本レポートと同じKEY WORD（biopsy）の最新刊レポート

よくあるご質問

OG Analysis社はどのような調査会社ですか?

OG Analysisは、10年以上の専門知識を持ち、半導体、エネルギー、化学品、自動車、農業など多様な市場調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行っています。もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。